Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abatacept in Hospitalized COVID-19 with Respiratory Compromise
NCT04472494Phase 2Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2020
- Primary completion
- Aug 2021
- Modality
- Fc-Fusion Proteins
- Countries
- 2
01
Overview
A Phase 2 trial of abatacept in coronavirus disease 2019 (COVID-19), sponsored by Bristol Myers Squibb. Started Oct 2020; status: terminated.
02
Drugs
abatacept
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04472494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04472494.